Zim Laboratories Ltd Q4 FY25 Results

Summary

Zim Laboratories Ltd has reported its Q4 & FY25 earnings. The total operating income grew by 3.2% YoY to ₹3,790 Mn. The export revenue stood at ₹3,125 Mn, contributing 82% to the total operating income. The EBITDA increased to ₹495 Mn with a margin of 13.1%. However, the PAT declined to ₹122 Mn due to increased finance and depreciation costs.

Key Highlights

1. 1

   Total Operating Income grew to ₹3,790 Mn (3.2% YoY)

2. 2

   Export revenue stood at ₹3,125 Mn (8.9% YoY)

3. 3

   EBITDA increased to ₹495 Mn, with margin improving to 13.1%

4. 4

   Revenue from New Innovative Products (NIP) rose by 81.8% YoY to ₹437 Mn

5. 5

   Revenue from Oral Thin Films grew 41.8% YoY to ₹186 Mn

6. 6

   Combined revenue from NIP, OTF, and licensing grew to ₹722 Mn from ₹438 Mn (19% up)

7. 7

   12 NIP products in pipeline; 7 filed in the EU, others across Pharmerging and RoW

8. 8

   5NIP+6 OTF dossiers filed in EU during the year

9. 9

   Secured 2 EU Marketing Authorizations for Dimethyl Fumarate (NIP) and Azithromycin Oral Suspension

10. 10

    Maintained gearing at 44% despite higher borrowings to support expansions

11. 11

    ₹365 Mn invested in Capex — including Urology Suite and Specialized Nutra Suite

12. 12

    R&D investment of ₹103 Mn focused on BE studies, regulatory filings, and innovation scale-up

13. 13

    EU GMP and NSF ANSI 455 -2 re- audit successfully completed